Álvarez-Sabín J, Yébenes M, Mar J, Oliva J, Becerra V, Arenillas JF, Martínez-Zabaleta M, Rebollo M, Segura T, Lago A, Gallego J, López-Gastón JI, Moniche F, Castillo J, Jiménez-Martínez MC, López-Fernández JC, Casado I, González-Rodríguez C, Escribano B, Casado MA, Masjuan J
¿Están infraestimados los costes hospitalarios del ictus en España?. Estudio CONOCES
LXIV Reunión de la Sociedad Española de Neurología. Barcelona, España. 20-24 nov 2012
De Andres F, Vivancos J, Barriga FJ, Díaz F, Izquierdo L, Ortega MA, Castillo L, Ximénez-Carrillo A, Gómez-Escalonilla CI, Torres C, de Salas-Cansado M, Casado MA, Soto J, Gil-Nuñez A
Healthcare resource utilization and costs of cardioembolic stroke in the region of Madrid, Spain: preliminary results of CODICE study
15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012
Sánchez-de la Rosa R, Sabater E, Casado MA
Cost analysis of glatiramer acetate versus fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012
Betegon L, Guilloteau I, Martin P, Woolmore A, Oyagüez I
The relative value of dasatinib versus imatinib as first-line treatment for chronic myeloid leukemiay
15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012
Cobo M, De Castro J, Isla D, Lozano V, Oyagüez I, Castro-Gomez AJ
Cost-effectiveness of erlotinib as first-line maintenance therapy for advanced non-small-cell lung carcinoma in patients EGFR WT and stable disease after four cycles of chemotherapy
15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012
Martin P, Betegon L, Guilloteau I, Lofgren C, Baradeau V, Oyagüez I